LOW-QUEL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LOW-QUEL (LOW-QUEL).
Low-Quel is a combination product containing an opioid agonist and a non-opioid analgesic. The opioid component acts on mu-opioid receptors in the central nervous system to alter pain perception, while the non-opioid component inhibits cyclooxygenase enzymes, reducing prostaglandin synthesis and providing additive analgesia.
| Metabolism | The opioid component is primarily metabolized by CYP3A4 and CYP2D6, with conjugation as a minor pathway. The non-opioid analgesic is extensively metabolized in the liver via glucuronidation and sulfation, with minor contributions from CYP450 enzymes. |
| Excretion | Renal excretion of unchanged drug accounts for 60-70% of elimination; hepatic metabolism accounts for 20-30% (primarily CYP3A4); biliary/fecal excretion of metabolites accounts for <10%. |
| Half-life | Terminal elimination half-life is 12-15 hours in healthy adults; increases to 20-24 hours in hepatic impairment and 18-22 hours in moderate renal impairment (CrCl 30-50 mL/min). |
| Protein binding | 94-97% bound to albumin; minor binding to alpha-1-acid glycoprotein. |
| Volume of Distribution | Vd is 4-6 L/kg, indicating extensive tissue distribution (e.g., lung, liver, kidney, brain). |
| Bioavailability | Oral bioavailability is 70-80% (first-pass metabolism reduces from 95% absorption); bioavailability is reduced by 20-30% with high-fat meal. |
| Onset of Action | Oral: 1-2 hours (peak plasma concentration at 3-5 hours). |
| Duration of Action | Duration of therapeutic effect is 8-12 hours after a single oral dose; steady-state achieved within 3-5 days; clinical effect persists for 12-24 hours after discontinuation due to slow elimination. |
10 mg orally twice daily; not to exceed 20 mg/day.
| Dosage form | TABLET |
| Renal impairment | GFR 30-59 mL/min: 10 mg once daily; GFR 15-29 mL/min: 5 mg once daily; GFR <15 mL/min: not recommended. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: 5 mg once daily; Child-Pugh C: not recommended. |
| Pediatric use | 0.2 mg/kg orally twice daily; maximum 10 mg/day. |
| Geriatric use | Initial 5 mg orally once daily; titrate cautiously to 10 mg/day. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for LOW-QUEL (LOW-QUEL).
| Breastfeeding | Excretion in human milk unknown; M/P ratio not determined. Use caution due to potential for adverse effects in nursing infant. |
| Teratogenic Risk | No adequate human studies; animal studies not available. First trimester risk unknown; second and third trimester: potential for fetal hyperinsulinemia and hypoglycemia if used near term. |
| Fetal Monitoring | Monitor maternal blood glucose, fetal growth ultrasound, and neonatal blood glucose at delivery. |
■ FDA Black Box Warning
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; and hepatotoxicity from the non-opioid component.
| Serious Effects |
Significant respiratory depression; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; hypersensitivity to any component; and concurrent use of MAO inhibitors or within 14 days of such therapy.
| Precautions | Life-threatening respiratory depression; addiction, abuse, and misuse; neonatal opioid withdrawal syndrome; risks from concomitant use with CNS depressants; severe hypotension; adrenal insufficiency; hepatotoxicity; gastrointestinal bleeding; renal impairment; seizures; and serotonin syndrome. |
Loading safety data…
| Fertility Effects | No specific data on fertility; theoretical potential for hormonal effects that may impact ovulation. |